4.7 Article

Antimicrobial Activities of Fidaxomicin

期刊

CLINICAL INFECTIOUS DISEASES
卷 55, 期 -, 页码 S143-S148

出版社

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis339

关键词

-

资金

  1. Optimer Pharmaceuticals, Inc.
  2. Merck
  3. Schering-Plough Pharmaceuticals
  4. Optimer Pharmaceuticals
  5. Theravance
  6. Cubist
  7. Pfizer
  8. Astellas
  9. Cerexa
  10. Impex Pharmaceuticals
  11. Novexel
  12. Novartis
  13. Clinical Microbiology Institute
  14. Genzyme
  15. Nanopacific Holdings
  16. Romark Laboratories
  17. Viroxis
  18. Warner Chilcott
  19. Avidbiotics
  20. GLSynthesis
  21. Immunome
  22. Toltec Pharma
  23. Salix Pharmaceuticals, GSK

向作者/读者索取更多资源

Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be <= 0.001-1 mu g/mL, with a maximum MIC for inhibition of 90% of organisms (MIC90) of 0.5 mu g/mL. Isolates from 2 phase III clinical trials demonstrated that fidaxomicin MICs of baseline isolates did not predict clinical cure, failure, or recurrence of C. difficile infections. No resistance to fidaxomicin developed during treatment in either study, although a single strain recovered from a cured patient had an elevated MIC of 16 mu g/mL at the time of recurrence. For 135 strains, OP-1118, a major metabolite, had an MIC for inhibition of 50% of organisms of 4 mu g/mL and an MIC90 of 8 mu g/mL. Changes in inoculum size (10(2)-10(5) colony-forming units/spot) or cation concentrations of calcium or magnesium appeared to have no effect on fidaxomicin MICs. Fidaxomicin has little or no activity against gram-negative aerobes and anaerobes or yeast.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据